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Background: The aim of our study is to evaluate the correlation between gynecological exam-
ination and magnetic resonance (MRI) ﬁndings for the assessment of local response in
cervical cancer patients treated with radiotherapy/chemotherapy (RT/ChT).
Patients and methods: This study is a retrospective review of 75 consecutive cervical cancer
patients from April 2004 to November 2009 treated with RT/ChT. Clinical and radiologi-
cal  data were subsequently analyzed. Patient’s median age was 51 with a FIGO stage from
Ib  to IVb. Individualized RT/ChT was administered with a median dose of 45 Gy. Sixty-
three patients received a complementary brachytherapy. Seventy-one patients received
chemotherapy on a weekly basis. Gynecological exam was performed 3 months and 6
months after treatment and these ﬁndings were compared to MRI results at the same time.Statistic analysis: We  used the Spearman’s Rho test to determine the correlation level betweenthe  clinical and radiological methods.
Results: A correlation of 0.68 (60%) was observed between the clinical and MRI ﬁndings at 3
months with a further increase of up to 0.86 (82.6%) at 6 months. In the few cases with a
poor correlation, the subsequent assessment and the natural history of the disease showed
a  greater value of the clinical exam as compared with the MRI ﬁndings.
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Conclusions: Physical exam remains an essential tool to evaluate the local response to RT/ChT
for  cervical cancer. The optimal clinical radiological correlation found at 6 months after
treatment suggests that the combination of gynecological examination and MRI are probably
adequate in patient monitoring.
©  2013 Greater Poland Cancer Centre. Published by Elsevier Urban & Partner Sp. z o.o. All
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with a complete physical examination (including vaginal vault
inspection plus bimanual pelvic examination) and radiological
assessment with MRI. All the MRIs were analyzed in a tumor
Table 1 – Clinical characteristics of the 75 patients.
Age
Median 51 years
FIGO stage
Ib2 8 (10.7%)
IIb 26 (34.6%)
IIIb 33 (44%)
IV 8 (10.7%)
Pathology
Squamous 59 (78.7%)
Adenocarcinoma 9 (12%)
Others 7 (9.3%)
Radiotherapy (median dose).  Background
ervical cancer is a very important issue in women’s health,
epresenting the second most common malignancy with an
ncidence of 500,000 patients annually worldwide [1,2].
The patients with locally advanced disease are optimally
reated with a combination of radio/chemotherapy (RT/ChT)
3,4]. However, there is no clear consensus for the optimal
ost-treatment evaluation.
The use of magnetic resonance imaging (MRI) for the eval-
ation of cervical cancer before and after treatment is well
stablished but there are some important and difﬁcult issues
hat must be addressed [5]. Some of them are the evaluation of
umor response to therapy and the distinction between post-
adiation changes and viable tumor.
The differential between residual tumor and radiation
hanges cannot be done with conventional magnetic reso-
ance images especially in the ﬁrst 3 months after therapy
6]. When changes in tumor occur as a consequence of biologi-
al and molecular changes, functional imaging techniques are
onsidered as an adjunctive tool in evaluating tumor features
Positron Emission Tomography, PET-scan).
We know that MRI  may be superior to computed tomo-
raphy (CT) for residual tumor detection because of its high
ontrast resolution. The residual disease has a high signal
ntensity on T2-weighted images, similar to the corresponding
rimary tumor [7]. Therefore, MRI  is considered the method of
hoice for follow-up after surgery or radiation treatment rec-
mmended by the FIGO guidelines because of its usefulness
n the detection of local disease recurrence. However, physi-
ian experience with radiological post-treatment changes is
ssential to prevent misinterpretations.
For these reasons, imaging techniques, especially magnetic
esonance imaging, are widely used as a complement to the
elvic exam [8].
.  Aim
he purpose of our study is to determine the correlation
egree between the clinical and radiological ﬁndings in the
valuation of treatment response to radio/chemotherapy in
atients with locally advanced cervical carcinoma.
.  Patients  and  methods total of 75 consecutive patients presenting with a diagnosis
f locally advanced cervical cancer treated with either radia-
ion alone or concomitant radio/chemotherapy in our hospital
etween April 2004 and November 2009 were included. Medianrights reserved.
age was 51 years (range: 29–81). Histopathological diagnosis
was squamous carcinoma in 59/75 patients (78.7%), adenocar-
cinoma in 9/75 (12%) and other carcinomas (adeno-squamous,
small cell) in 7/75 patients (9.3%).
Patients were staged using the 1988 FIGO classiﬁcation
(Fédération Internationale de Gynécologie Obstétrique) [9].
The main clinical characteristics are summarized in Table 1.
Node staging was performed prior to radiotherapy (RT) by
laparoscopic lymphadenectomy in 64 patients (85.33%): pelvic
lymphadenectomy in 29 patients (38.7%) and pelvic plus para-
aortic lymphadenectomy in 35 patients (46.7%).
All patients were treated with external beam radiotherapy
(EBRT): pelvic only in 60 patients and both pelvic and para-
aortic in 15 patients. Treatment was performed using 6 MV or
18 MV photons from a Linear Accelerator with multileaf col-
limator after 3D planning. The total median dose was 45 Gy,
with daily fractions of 1.8–2 Gy, once a day, 5 days per week.
Seventy-one patients received concomitant RT–ChT based on
platin compounds and only 4/75 patients did not undergo ChT
(elderly and/or low performance status).
Sixty-three patients (84%) received brachytherapy (BT) in
addition to EBRT. Within this group, 54 patients received
low-dose rate BT (median dose: 30 Gy at point A) and the 9
remaining patients received high-dose rate BT (median dose:
22 Gy at point A). The treatment was completed with an EBRT
parametrial boost with a median dose of 14 Gy in 41 patients
(54.6%).
Magnetic Resonance Imaging and Abdominal CT scan were
performed in all patients before RT. The treatment response
was evaluated 3 and 6 months after the completion of therapyPelvic 60 (80%)
Paraaortic 15 (20%)
Chemotherapy
Yes/no 71/4
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board and were compared to physical examination. Patients
underwent follow up every 3–4 months for the ﬁrst 2 years
and then every 6 months afterwards.
3.1.  MRI  protocol
MR  imaging was performed using a 1.5-T (Siemens). The proto-
col, transverse and sagittal T1-weighted spin-echo (SE) images
and transverse T1-weighted fat-saturated images of the pelvis
were obtained before and after contrast enhancement. Trans-
verse and sagittal T2-weighted fast SE sequences of the pelvis
were also obtained. MR  images were evaluated by gyneco-
logical radiologists and patients were classiﬁed as complete
response (CR), partial response (PR), disease progression (DP)
or stable disease (SD).
3.2.  Assessment  of  the  correlation
If physical examination and radiological evaluation shared the
same features, this was considered as correlation. In the cases
of no correlation, when physical examination ﬁndings showed
a CR and MRI  reported a PR, both examinations were repeated
3 months after or a PET-scan was performed. If there was a CR
on MRI  but a PR in the physical examination, we performed a
vaginal vault cytology or biopsy of the suspicious area. Finally,
if there was a DP on MRI  not evidenced in the physical exam-
ination, we performed a PET-scan.
4.  Statistical  analysis
The correlation between the MRI  and clinical ﬁndings was
assessed by Spearman’s rho (rank correlation) test. “r” val-
ues ≥0.75, 0.74–0.50 and <0.50 were considered to represent a
very good correlation, good correlation, and poor correlation,
respectively. Actuarial survival curves were plotted accord-
ing to the Kaplan–Meier method. All statistical analyses were
performed with the SPSS statistical package, version 18.0. p-
Values <0.05 were considered signiﬁcant.
5.  Results
Follow-up and clinical outcome data were available in 66 of
the 75 patients treated (88%). The mean follow-up was 31.1
months (range: 3.2–74.2). Twenty-two patients died (29.3%),
with a median survival time of 54.1 months (95% conﬁdence
interval (CI) 47.2–61 months).
Local relapse was observed in 21 patients (28%). Six patients
had a vaginal compromise (28.6%); 3 of these received a BT
rescue achieving local control. Seven patients had lymph
node metastasis and 15 patients showed distant metastasis
(6 liver metastasis, 2 lung, 3 bone, and 4 peritoneal carcino-
matoses).
The median local relapse-free survival for the entire series
was 54 months (95% CI 46.8–61.2) and the median metastasis-
free survival was 52.6 months (95% CI 45.3–59.9).iotherapy 1 8 ( 2 0 1 3 ) 214–219
5.1.  Clinical–radiological  correlation  in  cervical  cancer
3 months  after  treatment
Gynecological exam and MRI  results of 71 patients were avail-
able 3 months after treatment. Only 4 patients were lost at
follow-up: one patient died due to febrile neutropenia and
sepsis, one patient had a peritonitis and could not be prop-
erly followed, one patient went to another institution and
the last one did not ﬁnally receive standard treatment due
to small cell histology. The assessment of local response
to treatment with physical exam and MRI  correlated in 45
patients (60%) and was discordant in [26] patients (34.7%).
According to the Spearman’s rho test, the correlation of
clinical–radiological assessment at 3 months was considered
good (r = 0.658, p < 0.0001) (Table 2a).
5.2.  Clinical–radiological  correlation  in  cervical  cancer
6 months  after  treatment
The second assessment was carried out at 6 months after
completion of treatment. 60 patients were available for the
analysis. Eleven patients were lost at follow-up between the
ﬁrst and second assessment; 8 of them with disease progres-
sion and the remaining 3 were followed in other institutions.
The clinical and radiological assessment had a posi-
tive correlation in 55/60 patients (91.67%). Within the ﬁve
non correlated cases, four patients initially had both clin-
ical and radiological partial response to the treatment in
the ﬁrst assessment but the second MRI showed a residual
tumor in the cervix (low-uptake and persistence of pelvic fat
parametrium changes) and the gynecological exam showed
complete response (Fig. 1). In the remaining patient, the dis-
cordance between clinical and radiological results was related
to the presence of pelvic infection hindering adequate clinical
assessment.
According to the Spearman’s rho test, the clinical and
radiological correlation in the second assessment was con-
sidered very good (r = 0.86, p < 0.0001) (Table 2b).
6.  Discussion
Accurate evaluation of local tumor response is essential
to determine the probability of disease control in locally
advanced cervical cancer. The lack of local control usually
precedes the development of widespread disease [10].
The incorporation of MRI in a routine practice has provided
a more  precise evaluation of cervical tumors in terms of vol-
ume, localization, presence of parametrial and/or uterosacral
inﬁltration and regional lymph node involvement [11]. To
accurately localize relapse, clinical examination may not be
enough and there are no established MRI  parameters for the
same purpose [12].
Therefore, MRI is widely accepted as a useful imaging tool
for the diagnosis, staging, planning and follow-up for cervical
cancer. There are many  clinical trials on MRI  in the diagno-
sis and staging of locally advanced cervical cancer. However,
these trials do not evaluate the monitoring and assessment
issues after radiation therapy.
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Table 2a – The correlation between the MRI  and clinical ﬁndings was assessed by Spearman’s rho test. A good correlation
were observed between the clinical and MRI  ﬁndings at 3 months.
MRI 3 months
Lost CRa PRb SDc PDd Total
Clinical 3 months
Lost 4 0 0 0 0 4
CR 0 25 17 0 0 42
PR 0 2 15 1 1 19
SD 0 0 0 1 0 1
PD 0 0 3 1 5 9
Total 4 27 35 3 6 75
a CR: complete response.
b PR: partial response.
c SD: stable disease.
d PD: progression disease.
Table 2b – The correlation increased to a very good correlation at 6 months.
MRI 6 months
Lost CR PR SD PD Total
Clinical 6 months
Lost  15 0 0 0 0 15
CR 0 38 3 1 2 44
PR 0 0 7 0 0 7
F
M
P
pSD 0 0 
PD 0 0 
Total 15 37 
ig. 1 – MRI  shows a patient in whom physical examination and
RI  diagnosis. Bulky cervical tumor sample occupies 2/3 of vagin
ara-axial and sagittal MRI  after treatment, showing persistent h
artial response. However, the physical examination reported co0 0 0 0
0 0 9 9
10 1 11 75
 imaging test is not consistent. (a) Para-axial and sagittal
a without inﬁltrating it. No parametrial inﬁltration. (b)
ypointense image in the cervix, which is classiﬁed as a
mplete response.
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Until recently, physical examination and cytology were the
only methods for disease follow-up, despite the lack of sen-
sitivity in differentiating ﬁbrosis from residual tumor. MRI
(before, during and after treatment) represents an invalu-
able tool because it allows differentiation of healthy tissue,
tumor and post-irradiation ﬁbrosis [13–15]. Ma  et al. observed
the signal intensity changes through the implementation of
MRI-T2 before treatment and at week 4 (a half of treatment).
These authors concluded that persistent high signal intensi-
ties in the tumor at mid  treatment predicted a high risk for
treatment failure, while a large reduction in signal intensity
predicted a favorable outcome. These authors did not perform
an evaluation at the end of treatment [16]. As pointed out by
Vincens et al. [17], MRI  assessment of residual post-ChT/RT
disease continues to be difﬁcult and the risk of false positives
is high. These authors reported a false positive rate of up to
50%.
Although the use of MRI  in daily practice is to assess tumor
response in cervical cancer patients, its real value in properly
assessing tumor outcome during follow-up still needs to be
elucidated. For this reason, we proposed the current study in
order to ﬁnd the grade of correlation between clinical exam-
ination and MRI  with tumor response evaluation at 3 and 6
months.
Literature review provides few data on this subject with
regard to both follow-up and clinical–radiological correla-
tion. In a recent study of 36 cases published in 2011, Engin
et al. [12] reported a correlation of 88.9% (32/36) r: 0.674
in the evaluation of response to treatment at 6 months.
The presence of edema, inﬂammatory phenomena, ﬁbrosis,
necrosis or hemorrhage may induce incorrect MRI  interpre-
tation. These authors recommend deﬁnitive evaluation of
post-irradiation response with MRI  6 months after therapy.
In the case of clinical–radiological discordance, they rec-
ommend transvaginal echo-guided biopsy or computerized
tomography-guided biopsy.
The clinical–radiological correlation found in our series at
3 months was 60% which is considered good with the Spear-
man  rho test (r: 0.658). At 6 months correlation improved up
to 91.7% (very good correlation, r: 0.860). Engin et al. obtained
similar results to our study in a single assessment at 6 months,
albeit with fewer cases (n: 36) (88.9%). The histologist and stag-
ing features between their series and the present series were
similar [12]
Rizzo et al. [18] reviewed the post-irradiation MRI in a series
of 17 patients and concluded that at 3 months conventional
MRI  inadequately differentiates the post-irradiation changes
of the residual tumor. They concluded that Diffusion Weighted
Magnetic Resonance (DWMR) should be considered as an addi-
tional tool in the follow-up of non-surgical cases. Levy et al.
[19] reported a similar conclusion.
Not all the studies coincide in indicating the importance
of MRI. Ryu et al. [20] concluded that PET scan was effective
in detecting early recurrences in cervical cancer patients and
that it could be a useful follow-up tool for cervical cancer. In
addition, a recent study by Yen [21] showed that for recurrent
cervical cancer, the beneﬁt of PET scan exceeded that of MRI
owing to PET’s ability to identify extrapelvic metastases and to
its higher sensitivity and speciﬁcity. In a review study, Elit et al.
[22] described the limited and heterogeneous results of MRIiotherapy 1 8 ( 2 0 1 3 ) 214–219
and post-irradiation cytology in the detection of recurrence in
asymptomatic women.
New functional MRI tools have also been evaluated. Harry
et al. [23] studied the effectiveness of DWMR  in the early evalu-
ation of response to RT–ChT at 14 days after initiation. Despite
the promising results as a predictor of response, larger studies
are needed because their series only included 25 cases. In this
sense, Saida et al. [24] studied a series of 46 cases measuring
the volume of the areas of high signal intensity in T2 immedi-
ately after ﬁnishing the treatment. They concluded that local
control depends more  on the diminishment of volume regis-
tered than the initial volume. As in other trials, no mention
was made of the clinical–radiological correlation. In a series
of 14 patients Zhang et al. [25] also studied the value of DWMR
in the immediate evaluation of radiological response without
assessing the grade of reliability on posterior outcome.
Much more  recently, the criteria of the American College
of Radiology insisted on MRI and PET scan as the most effec-
tive method for post-ChT–RT follow-up of locally advanced
cervical cancers [4]. However, the value of all these imaging
techniques in the follow-up of these patients is being dis-
cussed and should be evaluated in large multicenter studies
prior to their inclusion in a usual clinical practice.
None of the studies cited, except that of Engin et al. [12],
investigated the clinical–radiological correlation. In our series
of 75 correlative cases, the concordance at 6 months was of
91.7%. The four cases with initial discordance showed CR on
posterior MRI, coinciding with the clinical ﬁnding of no per-
sistence. This fact indicates a great value and reliability of the
optimal gynecological examination. This conﬁrms the opinion
of other authors [17] with regard to false positives in the early
post-treatment MRI.
7.  Conclusion
Gynecological examination is an essential part in the early
assessment of the local response to the treatment of RT/ChT in
cervical cancer. The MRI limitation in the ﬁrst 3 months after
treatment suggests the need to include other imaging tools to
improve the accuracy in this time period. The optimal clini-
cal radiological correlation found at 6 months after treatment
suggests that the combination of gynecological examination
and MRI are probably adequate in patient monitoring.
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